Yüklüyor......
Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
OBJECTIVE: Bevacizumab was recently approved by the US Food and Drug Administration for use in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) when no more than two prior cytotoxic regimens have been used; due to concerns...
Kaydedildi:
| Yayımlandı: | J Gynecol Oncol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4944014/ https://ncbi.nlm.nih.gov/pubmed/27329195 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3802/jgo.2016.27.e47 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|